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Background: The aim of this study was to investigate the predisposition to different
types of allopurinol-induced cutaneous adverse drug reactions (CADR), including
Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n =
13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and
Maculopapular eruption (MPE; n = 7), conferred by HLA-B∗58:01 in a Thai population.
Methods: This case-control association study compares 30 patients with
allopurinol-induced CADR, allopurinol-tolerant control patients (n = 100), and a
Thai general population (n = 1095). Patients’ human leukocyte antigen type B (HLA-B)
alleles were genotyped by using a two-stage sequence-specific oligonucleotide
probe system.
Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients
were found to be at least heterozygous for HLA-B∗58:01, compared to only 4.0%
in allopurinol-tolerant patients (p < 0.001). Odds ratio (OR) for the association of
HLA-B∗58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI:
74.8–6475.0). TheHLA-B∗58:01 allele was present in all patients with allopurinol-induced
SJS-TEN (OR = 579.0, 95%CI: 29.5–11362.7, p < 0.001) and DRESS (OR 430.3,
95%CI: 22.6–8958.9, p< 0.001). Additionally, OR of HLA-B∗58:01was highly significant
in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9–1497.0, p < 0.001).
Conclusion: In this study we confirmed the association between HLAB∗58:01
and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an
association between HLA-B∗58:01 and allopurinol-induced DRESS and MPE in this
population. Therefore, HLA-B∗58:01 can be used as a pharmacogenetic marker for
allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest
that screening for HLA-B∗58:01 alleles in patients who will be treated with allopurinol
would be clinically helpful in preventing the risk of developing CARD in a Thai patients.
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Summary
• Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced
CADR in patients of Thai ancestry.
• In this study we confirmed the association between HLA-B∗58:01 and
allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population.
• Regarding to our findings, the pharmacogenetic interpretation could be generalized to
drug hypersensitivity including DRESS, SJS-TEN, and MPE.
Keywords: HLA-B∗58:01, allopurinol, Thai, SJS, TEN, DRESS, MPE, drug hypersensitivity
INTRODUCTION
In this last decade, pharmacogenetic studies have shown a strong
association between human leukocyte antigen (HLA) alleles
and susceptibility to drug hypersensitivity reactions (Sukasem
et al., 2014). HLA genes are a major contributor to drug
hypersensitivity involving direct stimulation of immune effector
cells and imitating an allergic reaction (Adam et al., 2011;
Cheng and Su, 2014). Currently, HLA-B alleles have been used
as pharmacogenetic markers to predict drug-induced cutaneous
adverse drug reactions (CADR; Daly, 2014; Sukasem et al.,
2014). The CADR such as Stevens-Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN), drug reaction with eosinophilia and
systemic symptoms (DRESS) or drug hypersensitivity syndrome
(DHS), and acute generalized exanthematous pustulosis (AGEP)
are often life-threatening. Maculopapular eruption (MPE) is
recognized as a mild form of hypersensitivity reaction (Lonjou
et al., 2008; Karlin and Phillips, 2014; Sasidharanpillai et al.,
2015).
Clinical presentation of SJS and TEN is characterized by rapid
progression of mucosal detachment and systemic symptoms
which may present as fever, mild elevation of hepatic enzymes,
and intestinal and pulmonary manifestation (Barvaliya et al.,
2011; Harr and French, 2012). SJS and TEN are differentiated by
the seriousness of skin detachment, which is limited in SJS (<10%
of body surface area; BSA) and more widespread in TEN (>30%
of BSA), with the intermediate stage (10–30% of BSA) of skin
detachment referred to as SJS/TEN overlapping (Aihara, 2011;
Harr and French, 2012). DRESS syndrome is an extremely serious
adverse effect referred to sometimes as DHS. It is characterized
by a skin rash, lymphadenopathy, fever, and can involve single or
multiple organs (Aihara, 2011; Fleming and Marik, 2011).
Allopurinol is a commonly prescribed medication that has
been used to inhibit xanthine oxidase in patients with gouty
arthritis, hyperuricemia, and in cancer patients undergoing
chemotherapy (Lam et al., 2013; Min et al., 2015). In Thailand,
allopurinol is a major cause of CADR and has been reported
as the second most frequent cause of CADR, including SJS-
TEN (SJS, TEN, SJS/TEN) and DRESS (Tassaneeyakul et al.,
Abbreviations: AGEP, Acute generalized exanthematous pustulosis; BSA, Body
surface area; CADR, Cutaneous adverse drug reactions; DRESS, Drug reaction
with eosinophilia and systemic symptoms; DHS, Drug hypersensitivity syndrome;
HLA, Human leukocyte antigen; MPE, Maculopapular eruption; SJS, Stevens-
Johnson syndrome; TEN, Toxic epidermal necrolysis; PPV, Positive predictive
value; NPV, Negative predictive value.
2009; Saokaew et al., 2014). Several studies have reported that
severe reactions to allopurinol are strongly associated with HLA-
B∗58:01, which is carried by 8–15% of Han Chinese and Thais
(Hung et al., 2005; Tassaneeyakul et al., 2009; Puangpetch et al.,
2015), but occurs relatively infrequently in Japanese (0.6%) and
European (0.8%) populations (Kaniwa et al., 2008; Lonjou et al.,
2008; Goncalo et al., 2013). According to the data from the
spontaneous reports by the Health Product Vigilance Center
of Thailand, allopurinol is the second ranked of common
culprit drugs, with at least 1488 patients suffering from SJS-
TEN and at least 75 patients suffering from DRESS during
the last 20 years (http://thaihpvc.fda.moph.go.th/thaihvc/Public/
News/uploads/hpvc_5_13_0_100526.pdf).
A previous publication from Thailand showed that the HLA-
B∗58:01 allele is a strong marker for allopurinol-induced CADR
in the Thai population (Tassaneeyakul et al., 2009). However,
that study reported only an association between allopurinol-
induced SJS-TEN and HLA-B∗58:01. More recently, a high
frequency of HLA-B∗58:01 was reported in Portuguese patients
with allopurinol-induced DRESS also (Goncalo et al., 2013).
Therefore, this study aims to determine the association of
allopurinol-induced CADR, which includes DRESS and SJS-
TEN, and also MPE, with the HLA-B∗58:01 allele in Thai
patients.
MATERIALS AND METHODS
Subjects and Characteristics
In this study, we carried out research as a retrospective and
prospective case-control study. From 2011 to 2015, patients
with allopurinol-induced CADR admitted to the allergy clinic of
Faculty of Medicine Ramathibodi Hospital, Mahidol University
were enrolled. Thirty patients with allopurinol-induced CADR
were categorized into DRESS (10 cases), SJS-TEN (13 cases)
and MPE (7 cases). Patients who had been taking allopurinol
for more than 6 months without evidence of cutaneous adverse
effects were recruited as allopurinol-tolerant controls (n = 100).
In addition, general population who had not taken allopurinol
and had no history of drug induced cutaneous adverse reactions
were included in this study. Both case and control subjects
were independently recruited with no family relationship. Data
for this healthy control group was obtained from 1095 subjects
undergoing HLA-B genotyping through the Laboratory for
Pharmacogenomics, Somdech Phra Debaratana Medical Center
(SDMC), Ramathibodi Hospital, Thailand.
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The study was performed and approved by the Ramathibodi
Hospital ethical review board, and informed consent was
obtained from all of the participants.
Diagnosis of Cutaneous Adverse Drug
Reactions (CADR)
All CADR patients were assessed by a dermatologist and
allergist who reviewed photographs, pathological slides, clinical
morphology, and medical records. The diagnosis of drug-
induced DRESS, SJS-TEN was made according to the RegiSCAR
criteria (Choudhary et al., 2013). In brief, DRESS was diagnosed
in patients presenting with fever, maculopapular rash with
internal organ involvement, and hematologic abnormalities. SJS
was diagnosed in patients with skin rash and mucosal erosion
covering up to 10% of BSA whereas SJS-TEN overlap was
diagnosed in patients with epidermal necrosis whose blistering
skin lesions affected between 10 and 30% of BSA. MPE was
diagnosed in patients presenting with danger signs in drug-
induced exanthema or covering 30% BSA with or without
associated systemic symptoms, but not fulfilling criteria for
DRESS (Pichler et al., 2002).
Genomic DNA Extraction
Blood samples were collected into EDTA tubes. DNA was
isolated using the MagNA Pure automated extraction system
(Roche Diagnostics, USA) based on magnetic-bead technology.
The quality of genomic DNA was assessed using a Nano
Drop ND-1000 to measure quantity and purity of genomic
DNA. All DNA was aliquotted and stored at −20◦C before
analysis.
HLA-B Typing
The HLA-B alleles were genotyped by the Polymerase Chain
Reaction-sequence specific oligonucleotide probe (PCR-SSOP)
principles with the commercial kit (LABType SSO HLA Typing
Kit; One Lambda Inc., CA, USA). Then, the HLA-B alleles
were carried out using LuminexTM Multiplex Technology
(Luminex R© IS 100, USA). Briefly, PCR products were hybridized
against a panel of oligonucleotide probes coated on polystyrene
microspheres that have sequences complementary to stretches
of polymorphic sequence within the target HLA-B alleles. The
amplicon-probe complex was visualized using a colorimetric
reaction and fluorescence detection technology. Data analysis
for the HLA-B assays were performed with HLA fusionTM 2.0
software.
Statistical Analysis
The association between HLA-B∗58:01 and allopurinol-induced
CADR was evaluated by comparing the group of individuals
with CADR with the allopurinol-tolerant groups and the general
population. Data were counted by presence or absence of HLA-
B∗58:01 allele. Chi-square test and Fisher’s exact test were used to
analyze the association between allopurinol-induced cutaneous
adverse reactions and HLA-B∗58:01. Statistical analysis was
performed using SPSS version 16.0 (SPSS Inc., Chicago,
IL, USA). The strength of association was estimated by
calculating the odds ratio (OR) with a 95% confidence
interval (CI). Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calculated.
P ≤ 0.05 (two-sided) were considered to indicate statistical
significance.
RESULTS
Subjects Clinical Characteristics
Of the 30 patients with CADR, 23 had underlying gout and
seven had hyperuricemia. Seventeen (56.7%) patients were male
and 13 (43.3%) were female, with an average age of 73.3 years
(range 30–88 years). The mean duration of allopurinol use was
16.4 ± 14.3 days with a mean dosage of 239.29 ± 87.0mg/day
(range, 100–600 mg/day).The mean interval from allopurinol
initiation to symptom onset was 22.2 ± 12.9 days (range,
7–42 days). The onset of symptoms for all patients was
within the first 2 months of allopurinol exposure. The most
common underlying were Hypertension consisting of 20 patients
(66.7%) followed by Chronic Kidney Disease (CKD) with 13
patients (43.3%) and Diabetes with 4 patients (13.3%). The
most common of co-medication was colchicine (19/30; 63.3%).
Patient’s characteristics, duration of allopurinol exposure to
symptom onset and the results of HLA-B genotyping are
summarized in Tables 1, 2.
TABLE 1 | Association of demographic data and Allopurinol-induced
cutaneous adverse drug reactions (CADR).
Demographic data Case (n = 30)
SEX (n/%)
Male 17/56.7
Female 13/43.3
Age (median/range) 73/30–88
UNDERLYING DISEASE (n/%)
Hypertension 20/66.7
Chronic kidney disease 13/43.3
Diabetes 4/13.3
CO-MEDICATION
Colchicine 19/63.3
Simvastatin 3/10.0
Prednisolone 2/6.7
DOSAGE OF ALLOPURINOL; mg/day 239.29 ± 87.0
(AVERAGE ± SD)
DURATION OF ALLOPURINOL EXPOSURE; DAYS 16.4 ± 14.3
(AVERAGE ± SD)
LABORATORY RESULT (AVERAGE ± SD)
Uric acid; mg/dL 6.58 ± 2.537
Blood Urea Nitrogen; mg/dL 43.64 ± 32.341
Creatinine; mg/dL 2.45 ± 5.246
Aspartate aminotransferase; mg/dL 63.19 ± 88.120
Alanine transaminase; mg/dL 71.26 ± 96.188
PHENOTYPE (n/%)
SJS-TEN 13/43.4
DRESS 10/33.3
MPE 7/23.3
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HLA-B∗58:01 in Cutaneous Adverse Drug
Reactions (CADR) Case-Control Study
To identify genetic markers for allopurinol–induced CADR
including DRESS, SJS-TEN, and MPE, we carried out a case-
control association study. Frequencies of HLA-B∗58:01 genotype
TABLE 2 | Summary of characteristic and genotyping data of
allopurinol-induced cutaneous adverse drug reactions (CADR) in
individuals.
No. Age/Sex Phenotype HLA-B*58:01 HLA-B genotyping
1 56/M DRESS Positive 4402:5801
2 72/F SJS Positive 5701:5801
3 78/F SJS Positive 3501:5801
4 68/F SJS Positive 4601:5801
5 85/F MPE Positive 4001:5801
6 48/F SJS Positive 1301:5801
7 68/M SJS Positive 1301:5801
8 74/M DRESS Positive 5201:5801
9 54/M SJS-TEN Positive 4001:5801
10 78/M SJS-TEN Positive 4403:5801
11 74/F SJS-TEN Positive 1502:5801
12 28/M DRESS Positive 3915:5801
13 37/F DRESS Positive 0801:5801
14 67/M MPE Negative 1301:5401
15 81/F DRESS Positive 1301:5801
16 76/F SJS Positive 5801:5801
17 76/M SJS Positive 4001:5801
18 73/M DRESS Positive 5201:5801
19 76/F SJS-TEN Positive 1513:5801
20 73/F SJS-TEN Positive 4601:5801
21 55/M SJS-TEN Positive 1502:5801
22 55/F DRESS Positive 5801:5801
23 78/M DRESS Positive 1502:5801
24 81/M DRESS Positive 5801:5801
25 61/M DRESS Positive 5101:5801
26 88/F MPE Positive 4001:5801
27 79/M MPE Positive 4001:5801
28 73/M MPE Positive 1301:5801
29 72/M MPE Positive 1802:5801
30 84/M MPE Positive 3901:5801
in the three groups are shown in Table 2. Of the 30 patients with
allopurinol-induced CADR, 29 patients (96.70%) carried HLA-
B∗58:01, while 4 of 100 (4.0%) allopurinol-tolerant controls and
111 of 1095 (10.1%) untreated controls carried this allele. The
frequency of HLA-B∗58:01 in subjects with allopurinol-induced
CADR was notably higher than in the allopurinol-tolerant group
(OR 696.00; 95% CI: 74.81–6475.01, p < 0.001) and general
population group (OR 257.08; 95% CI: 34.68–1905.57). In our
HLA-B genotyping studies, no other alleles showed significant
association with allopurinol-induced CADR (Table 3).
By extending our investigation for other HLA-B alleles, we
found that HLA-B∗40:01 (29.0%, OR= 0.45; 95% CI, 0.09–2.13),
HLA-B∗46:01 (25.0%, OR = 0.21; 95% CI, 0.05–0.96), and HLA-
B∗51:01 (12.0%, OR= 0.25; 95%CI, 0.03–2.03) was detectedmore
frequently in control group than in allopurinol-induced CADR
groups (16.7, 6.7, and 3.3%, respectively). However, there were
no statistically significant differences (p> 0.05) between case and
control groups (Table 3).
HLA-B∗58:01 in SJS-TEN and DRESS
Cases-Controls Study
The relationship between HLA-B∗58:01 and allopurinol-induced
SJS-TEN and DRESS was subsequently studied in this study. All
23 (100%) patients with allopurinol-induced SJS-TEN (n = 13)
and DRESS (n = 10) cases had HLA-B∗58:01 (three patient
was homozygous for HLA-B∗58:01). As shown in Table 4, the
HLA-B 58:01 allele occurred at significantly increased frequencies
among the allopurinol-induced SJS-TEN patients compared to
the two control groups (OR = 579.00, 95%CI: 29.50–11362.67
andOR= 238.40, 95%: 14.08–4037.80). Sensitivity and specificity
of HLA-B∗58:01 for prediction of allopurinol-induced SJS-TEN
were 100.00 and 96.0%. In addition, the PPV and NPV of
the HLA-B∗58:01 allele was also 76.47 and 100.0%, respectively
(Table 7).
In addition, the HLA-B∗58:01 allele was associated with a
higher risk of DRESS (OR 430.33, 95%CI: 22.64–8958.88, p <
0.001 and OR 185.42, 95%CI: 10.79–3185.84, p < 0.001) when
compared with allopurinol tolerant patients and the general
population, respectively (Table 5). Sensitivity and specificity
of HLA-B∗58:01 for prediction of allopurinol-induced DRESS
were 100.00 and 96.0%. In addition, the PPV and NPV of
TABLE 3 | The association of individual HLA-B allele with allopurinol-induced cutaneous adverse drug reactions (CADR).
HLA-B allele Allopurinol-induced
CADR (n = 30) (%)
Allopurinol tolerant
control (n = 100) (%)
General population
(n = 1095) (%)
CADR case vs. allopurinol
tolerant control
CADR case vs. general
population
OR (95% CI) p-value OR (95% CI) p-value
58:01 29 (96.7) 4 (4.0) 111 (10.1) 696.00 (74.81–6475.01) <0.001 257.08 (34.68–1905.57) <0.001
13:01 5 (16.7) 9 (9.0) 137 (12.5) 2.02 (0.62–6.58) 0.242 1.40 (0.53–3.71) 0.501
15:02 3 (10.0) 20 (20.0) 161 (14.7) 0.44 (0.12–1.6) 0.218 0.65 (0.19–2.15) 0.475
40:01 5 (16.7) 29 (29.0) 162 (14.8) 0.49 (0.17–1.40) 0.184 1.15 (0.43–3.05) 0.776
46:01 2 (6.7) 25 (25.0) 227 (20.7) 0.21 (0.05–0.96) 0.051 0.27 (0.06–1.16) 0.077
51:01 1 (3.3) 12 (12.0) 65 (5.9) 0.25 (0.03–2.03) 0.196 0.55 (0.07–4.08) 0.556
Frontiers in Pharmacology | www.frontiersin.org 4 July 2016 | Volume 7 | Article 186
Sukasem et al. Pharmacogenetics of Allopurinol Hypersensitivity in Thai Patients
the HLA-B∗58:01 allele was also 76.43 and 100.0%, respectively
(Table 7).
HLA-B∗58:01 in MPE Cases-Controls Study
Of the seven patients with allopurinol-induced MPE, 6
of 7 (85.7%) patients had HLA-B∗58:01 whereas 4 (4.0%)
of allopurinol-tolerant patients had HLA-B∗58:01. The one
patient with MPE who did not have the HLA-B∗58:01 allele
carried HLA-B∗13:01/54:01. In this study, the OR of HLA-
B∗58:01 was highly significant in the allopurinol-induced MPE
patients (OR 144.00, 95%CI: 13.85–1497.03, p < 0.001), as
shown in Table 6. Sensitivity and specificity of HLA-B∗58:01
for prediction of allopurinol-induced MPE were 85.71 and
96.0%, respectively. In addition, the PPV and NPV of the
HLA-B∗58:01 allele was also 60.0 and 98.97%, respectively
(Table 7).
DISCUSSION
In the present study, the case–control analysis included 30
cases of allopurinol-induced CADR, which included DRESS (10
cases), SJS-TEN (13 cases), and MPE (7 cases). The association
study in Thai patients examined only a limited phenotype of
allopurinol-induced SJS-TEN (Tassaneeyakul et al., 2009). In this
study we confirmed the association between HLA-B∗58:01 and
allopurinol-induced SJS-TEN (OR= 579.0) in a Thai population.
In addition, we identified an association between HLA-B∗58:01
and allopurinol-induced DRESS and MPE with OR 430.3 and
144.0, respectively. Thus, the HLA-B∗58:01 is associated with
allopurinol-induced CADR including SJS-TEN, DRESS andMPE
in a Thai population.
HLA-B∗58:01 was the most predominant allele associated
with allopurinol-induced CADR and was not found in only one
patient who had allopurinol-inducedMPE (HLA-B∗13:01/54:01).
TABLE 4 | The association of individual HLA-B allele with allopurinol-induced SJS-TEN.
HLA-B allele Allopurinol-induced
SJS-TEN (n = 13) (%)
Allopurinol tolerant
control (n = 100) (%)
General population
(n = 1095) (%)
SJS-TEN cases vs. Allopurinol
tolerant control
SJS-TEN cases vs. general
population
OR (95% CI) p-value OR (95% CI) p-value
58:01 13 (100.0) 4 (4.0) 111 (10.1) 579.00 (29.50–11362.67) <0.001 238.40 (14.08–4037.80) <0.001
13:01 2 (15.4) 9 (9.0) 137 (12.5) 1.84 (0.35–9.62) 0.471 1.27 (0.28–5.80) 0.756
15:02 2 (15.4) 20 (20.0) 161 (14.7) 0.73 (0.15–3.55) 0.694 1.05 (0.23–4.80) 0.945
40:01 2 (15.4) 29 (29.0) 162 (14.8) 0.45 (0.09–2.13) 0.312 1.05 (0.23–4.77) 0.953
46:01 2 (15.4) 25 (25.0) 227 (20.7) 0.55 (0.11–2.63) 0.450 0.70 (0.15–3.16) 0.638
51:01 0 (0.0) 12 (12.0) 65 (5.9) 0.26 (0.01–4.69) 0.363 0.58 (0.03–9.91) 0.709
TABLE 5 | The association of individual HLA-B allele with allopurinol-induced DRESS.
HLA-B allele Allopurinol-induced
DRESS (n = 10) (%)
Allopurinol tolerant
control (n = 100) (%)
General population
(n = 1095) (%)
DRESS cases vs. allopurinol
tolerant control
DRESS cases vs. general
population
OR (95% CI) p-value OR (95% CI) p-value
58:01 10 (100.0) 4 (4.0) 111 (10.1) 430.33 (22.64–8958.88) <0.001 185.42 (10.79–3185.84) <0.001
13:01 1 (10.0) 9 (9.0) 137 (12.5) 1.12 (0.13–9.90) 0.917 0.78 (0.10–6.18) 0.812
15:02 1 (10.0) 20 (20.0) 161 (14.7) 0.44 (0.05–3.72) 0.454 0.64 (0.08–5.12) 0.678
40:01 1 (10.0) 29 (29.0) 162 (14.8) 0.27 (0.03–2.25) 0.225 0.64 (0.08–5.08) 0.673
46:01 0 (0.00) 25 (25.0) 227 (20.7) 0.14 (0.01–2.49) 0.181 0.18 (0.01–3.11) 0.240
51:01 1 (10.0) 12 (12.0) 65 (5.9) 0.82 (0.09–7.01) 0.852 1.76 (0.22–14.11) 0.594
TABLE 6 | The association of individual HLA-B allele with allopurinol-induced MPE.
HLA-B allele Allopurinol-induced
MPE (n = 7) (%)
Allopurinol tolerant
control (n = 100) (%)
General population
(n = 1095) (%)
MPE case vs. Allopurinol
tolerant control
MPE case vs. general
population
OR (95% CI) p-value OR (95% CI) p-value
58:01 6 (85.7) 4 (4.0) 111 (10.1) 144.00 (13.85–1497.03) <0.001 53.19 (6.35–445.85) <0.001
13:01 2 (28.6) 9 (9.0) 137 (12.5) 4.04 (0.68–23.91) 0.123 2.80 (0.54–14.56) 0.222
15:02 0 (0.0) 20 (20.0) 161 (14.7) 0.26 (0.01–4.77) 0.366 0.39 (0.02–6.79) 0.515
40:01 3 (42.9) 29 (29.0) 162 (14.8) 1.84 (0.39–8.72) 0.445 4.32 (0.96–19.48) 0.057
46:01 0 (0.0) 25 (25.0) 227 (20.7) 0.20 (0.01–3.58) 0.272 0.25 (0.01–4.47) 0.349
51:01 0 (0.0) 12 (12.0) 65 (5.9) 0.47 (0.03–8.78) 0.615 1.05 (0.06–18.57) 0.974
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TABLE 7 | Sensitivity/Specificity/Positive predictive value (PPV)/Negative predictive value (NPV).
HLA-B*58:01 vs. allopurinol tolerant control (%) vs. general population (%)
Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
CADR 96.67 96.00 87.88 98.97 96.67 89.86 20.71 99.90
SJS-TEN 100.00 96.00 76.47 100.00 100.00 89.86 10.48 100.00
DRESS 100.00 96.00 76.43 100.00 100.00 89.86 8.26 100.00
MPE 85.71 96.00 60.00 98.97 85.71 89.86 5.13 99.90
Moreover, there was no significantly associated CADR with any
other HLA-B alleles such as HLA-B∗13:01, indicating that HLA-
B∗58:01 has an important role in the progression of allopurinol-
related CADR in the Thai population. The odds ratio (OR) for the
association of HLA-B∗58:01 with combined CADR phenotypes
in this population was 696.00 (p < 0.01). Using the allopurinol
tolerant group as the control, the HLA-B∗58:01 allele had
95.20% sensitivity and 100% specificity for diagnosing CADR.
This strong association also has been observed in other Asian
countries (Hung et al., 2005; Kaniwa et al., 2008; Jung et al., 2011;
Kang et al., 2011).
Previous study has proposed association of immune
mechanisms in the development of several forms of allopurinol-
induced CADR. Hung et al. has shown that the HLA-B∗58:01
allele is a strong genetic factor in the incidence of CADR
(SJS-TEN, and DRESS) for Han Chinese taking allopurinol
(Hung et al., 2005). Although, Tassaneeyakul et al. was the first
to identify an association betweenHLA-B∗58:01 and allopurinol-
induced SJS-TEN in Thai (Tassaneeyakul et al., 2009), no
published data have yet confirmed such a strong correlation
of HLA-B∗58:01 and allopurinol-induced DRESS and MPE in
Thai patients. Recently, we identified an association between
HLA-B∗58:01 and allopurinol-induced DRESS and MPE in Thai
population.
This finding reveals that the risk of developing DRESS
among those allopurinol users with HLA-B∗58:01 is significantly
increased by 430.3 times compared to allopurinol-tolerant
controls. The association is 100% in that the HLA-B∗58:01
was present in all 10 patients with allopurinol-induced DRESS,
similar to the study in Han Chinese and Japanese populations
(Hung et al., 2005; Kaniwa et al., 2008). In this study, we
also confirmed a strong association between the allele HLA-
B∗58:01 and susceptibility to allopurinol-induced SJS-TEN in
Thai patients. Based on the strong association of the presence
of HLA-B∗58:01 and DRESS and SJS-TEN, it is presumed that
the attributable risk of CADR due to the existence of this allele
is larger—as high as 8% in Thailand (Puangpetch et al., 2015)—
indicating that HLA-B∗58:01 is associated with the pathogenesis
of allopurinol-induced CADR regardless of the phenotype or
severity. This is in contrast to carbamazepine-induced SJS-
TEN, with which HLA-B∗15:02 only shows association with only
SJS-TEN (Suresh Kumar et al., 2005; Phillips et al., 2011; Lee et al.,
2014).
Moreover, MPE has been considered to be distinct from SJS-
TEN, characterized as macule and papule rash, with symmetry
on both left and right of body and especially on the face, palms
and feet, and with no detachment on the body surface area and
no systemic involvement (Pichler et al., 2002). The association
of HLA-B∗58:01 with MPE is less well studied (Profaizer and
Eckels, 2012). Recently, Cao et al. found that all 22 Han
Chinese with MPE in that study were HLA-B∗58:01 positive
(Cao et al., 2012). Among 12 Australian patients, none was
HLA-B∗58:01 positive, and three of four had MPE, which was
statistically significantly different from the allopurinol-tolerant
group (Lee et al., 2012). In recent times, we investigated an
association betweenHLA-B∗58:01 and allopurinol-inducedMPE.
By comparison, the OR of HLA-B∗58:01 was 144.0 and 53.2
between the MPE patients with the allopurinol-tolerant and
untreated Thai population groups. However, a major limitation
of this study was the sample size of the MPE patients available
for the analysis. Confirmation of this result in an independent
cohort of larger sample size would allow us to determine
whether the HLA-B∗58:01 identified in this study is definitely
associated with the development of allopurinol-induced MPE
and provide more accurate estimates of their impact in the
clinical practice.
Commonly, allopurinol is associated with CADR ranging
from mild skin rash, such as MPE to life-threatening severe
cutaneous adverse reactions including DRESS and SJS-TEN (Ng
et al., 2016). Interestingly, HLA-B∗40:01 was found much more
frequently in the allopurinol-induced MPE (n = 3/7; 42.9%)
than others allopurinol-induced SJS-TEN (n = 2/13; 15.4%) and
no HLA-B∗40:01 was observed in allopurinol-induced DRESS
cases. Furthermore, homozygous HLA-B∗58:01 was found only
in severe cutaneous adverse drug reaction, that included SJS-
TEN and DRESS. Hence, the complementary alleles with HLA-
B∗58:01 carriers might be identified as a marker influencing
susceptibility to different types of allopurinol-induced CADR
in Thai population. Moreover, Grover et al. found that HLA-
B∗40:01 could be a protective marker for carbamazepine-induced
CADR (OR = 0.32; 95% CI = 0.19–0.53; P = 1.08 × 10−5;
Grover and Kukreti, 2013). In this study, HLA-B∗40:01 (29.0%),
HLA-B∗46:01 (25.0%), and HLA-B∗51:01 (12.0%) was higher in
allopurinol-tolerant than in allopurinol-induced CADR groups
(16.7, 6.7, and 3.3%, respectively, p> 0.05). This possibly suggests
that the both alleles might be protective markers for allopurinol-
induced CADR. However, the number of patients may not be
enough to reveal all the assumptions, further investigation using
a large number of samples and well-designed study is required to
better understand.
Practically, colchicine is an immune-modulating agent
which is normally prescribed with allopurinol for acute gout
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FIGURE 1 | Pharmacogenomics card and clinical interpretation; (A) clinical interpretation before this study, (B) revised clinical interpretation after this
study.
prophylaxis. Ryu et al. found that the use of colchicine was the
clinical risk factor for adverse events when using allopurinol
(Ryu et al., 2013). In this study, 63.3% (n = 19/30) of patients
with allopurinol-induced CADR were treated with colchicine as
a co-medication. Both allopurinol and colchicine are potential
offending drugs in the present case of CADR. Commonly,
allopurinol, one of the most frequent causes of SJS and TEN.
Colchicine is also associated, but to a lesser degree (Ryu et al.,
2013). However, the risk of allopurinol-induced CADR in
Concurrent administration with colchicine in patients carried
HLA-B∗58:01 allele has not yet been evaluated.
With evidence support the association of the HLA-B∗58:01
allele with allopurinol-induced CADR, CPIC guidelines
recommend the use of pharmacogenomics tests for presence
of the HLA-B∗58:01 allele before initiating allopurinol therapy
in patients (Hershfield et al., 2013). After patients have
taken an HLA test, their results are entered into a plastic
“pharmacogenomic wallet card,” which basically contains the
genomic results of those related to the risk of CADR. This card
can be carried around and shown to different doctors in the
future (Figures 1A,B). Currently, there were over 1400 patients
which were genotyped and delivered the pharmacogenomic
cards for screening HLA-B∗58:01 before allopurinol prescription
from our setting. The pharmacogenetics interpretation has
been changed from “High risk for allopurinol-induced SJS-
TEN” (Figure 1A) to be “High risk for allopurinol-induced
SJS-TEN, DRESS and MPE” (Figure 1B) from our finding in
Thai population. Physicians and national policy makers should
consider genetic screening for the HLA-B∗58:01 alleles prior to
initiation of allopurinol therapy in Thai patients.
In summary, a strong association between
allopurinol-induced CADR and the HLA-B∗58:01 allele was
confirmed. Incidence of the HLA-B∗58:01 allele is strongly
associated with individuals who are at risk for allopurinol-
induced DRESS, SJS-TEN, and MPE in the Thai population.
Our results suggest that the screening tests for the HLA-
B∗58:01 allele in patients who will be treated with allopurinol
would be clinically helpful in reducing the risk of developing
CADR.
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